Intra-articular injection of etanercept versus glucocorticoids in rheumatoid arthritis patients

[1] McAllister K(2011)Genetics of rheumatoid arthritis: GWAS and beyond Open Access Rheumatol 3 3-46

[2] Eyre S(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

[3] Orozco G(2005)Injectable corticosteroids in treatment of arthritis of the knee Am J Med 118 1208-1214

[4] Smolen JS(2006)Should we be using intra-articular tumor necrosis factor blockade in inflammatory mono-arthritis? J Rheumatol 33 1934-1935

[5] Landewé R(2016)Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and mono-arthritis flare Int J Immunopathol Pharmacol 29 252-266

[6] Bijlsma J(2014)Anti-TNF therapy: past, present and future Int Immunol 27 55-62

[7] Burmester G(1999)A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253-259

[8] Chatzidionysiou K(2013)Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers Joint Bone Spine 80 165-170

[9] Dougados M(2010)2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 2569-2581

[10] Nam J(1995)Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44-48

[1] McAllister K(2011)Genetics of rheumatoid arthritis: GWAS and beyond Open Access Rheumatol 3 3-46

[2] Eyre S(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

[3] Orozco G(2005)Injectable corticosteroids in treatment of arthritis of the knee Am J Med 118 1208-1214

[4] Smolen JS(2006)Should we be using intra-articular tumor necrosis factor blockade in inflammatory mono-arthritis? J Rheumatol 33 1934-1935

[5] Landewé R(2016)Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and mono-arthritis flare Int J Immunopathol Pharmacol 29 252-266

[6] Bijlsma J(2014)Anti-TNF therapy: past, present and future Int Immunol 27 55-62

[7] Burmester G(1999)A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253-259

[8] Chatzidionysiou K(2013)Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers Joint Bone Spine 80 165-170

[9] Dougados M(2010)2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 2569-2581

[10] Nam J(1995)Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44-48